Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland-Reference-Cited by-同舟云学术

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland

Published:2016-08-11 Issue:1 Volume:20 Page:8-18
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Parker Christopher¹,Woods Beth²,Eaton James¹,Ma Esprit³,Selby Ross⁴,Benson Eugene⁴,Engstrom Andreas⁵,Sajosi Peter⁶,Briggs Andrew¹⁷,Bonthapally Vijayveer⁶

Affiliation:

1. ICON Health Economics & Epidemiology, Abingdon, UK;

2. Centre for Health Economics, University of York, York, UK;

3. Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA;

4. Takeda UK Ltd, Buckinghamshire, UK;

5. Takeda Pharma AB, Stockholm, Sweden;

6. Millennium Pharmaceuticals Inc., Cambridge, MA, USA,a wholly owned subsidiary of Takeda Pharmaceutical Company Limited;

7. Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1219358

Reference49 articles.

1. Cancer Research UK. Hodgkin lymphoma incidence statistics. Cancer Research UK Cancer statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/hodgkin-lymphoma/incidence. Accessed July 6, 2015

2. ISD Scotland. Scottish Cancer Registry. Scottish Cancer Registry Cancer Statistics Hodgkin Lymphoma. http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Hodgkins-Disease/. Accessed July 6, 2015

3. European Medicines Agency. Public summary of opinion on orphan designation. EU/3/08/596. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006354.pdf. Accessed March 17, 2016

4. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

5. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China;Health Economics Review;2024-06-06

2. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review;European Journal of Clinical Pharmacology;2023-09-01

3. A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma;Expert Review of Hematology;2022-07-03

4. The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin’s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice;Clinical oncohematology;2022

5. Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review;Expert Review of Pharmacoeconomics & Outcomes Research;2021-05-02